Phase II study of paclitaxel combined with capecitabine as second-line treatment for advanced gastric carcinoma after failure of cisplatin-based regimens

Cancer Chemotherapy and Pharmacology

Volumn 64, Issue 3, 2009, Pages 549-555

  Baize, N ^a   Abakar Mahamat, A ^a   Mounier, N ^a   Berthier, F ^a   Caroli Bosc, F X ^a,b  

^a UNIVERSITÉ CÔTE D'AZUR   (France)

^b ANGERS UNIVERSITY HOSPITAL   (France)

Author keywords

Advanced gastric cancer; Capecitabine; Paclitaxel; Second line chemotherapy

Indexed keywords

CAPECITABINE; CISPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; PACLITAXEL; RANITIDINE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DEATH; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HEMATOLOGIC DISEASE; HUMAN; HYPERSENSITIVITY REACTION; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; STOMACH CARCINOMA; THROMBOCYTOPENIA; TREATMENT FAILURE; VOMITING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PACLITAXEL; STOMACH NEOPLASMS; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 67449092163     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-008-0903-7     Document Type: Article

References (33)

1. F Kamangar GM Dores WE Anderson 2006 Patterns of cancer incidence, mortality and prevalence across 5 continents: defining priorities to reduce cancer disparities in different geographic regions of the world J Clin Oncol 24 2537 2550
2. KD Crew AI Neugut 2006 Epidemiology of gastric cancer World J Gastroenterol 12 354 362 (Pubitemid 43329250)
3. JB Dupont JR Lee GR Burton I Cohn Jr 1978 Adenocarcinoma of the stomach: review of 1497 cases Cancer 41 941 953
4. AM Murad FF Santiago A Petroianu PR Rocha MA Rodrigues M Rausch 1993 Modified therapy with 5 fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer Cancer 72 37 41 (Pubitemid 23182046)
5. B Glimelius K Hoffman U Haglund O Nyren PO Sjoden 1994 Initial or delayed chemotherapy with best supportive care in advanced gastric cancer Ann Oncol 5 189 190 (Pubitemid 24062577)
6. S Pyrhonen T Kuitunen P Nynandoto M Kouri 1995 Randomized comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer Br J Cancer 71 587 591
7. B Glimelius K Ekstrom K Hoffman W Graf PO Sjoden U Haglund C Svensson LK Enander T Linne H Sellstrom R Heuman 1997 Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer Ann Oncol 8 163 168 (Pubitemid 27112884)
8. AD Wagner W Grothe J Haerting G Kleber A Grothey WE Fleig 2006 Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data J Clin Oncol 24 2903 2909 (Pubitemid 46630593)
9. E Van Cutsem VM Moiseyenko S Tjulandin A Majlis M Constenla C Boni A Rodrigues M Fodor Y Chao E Voznyi ML Risse J Ajani 2006 Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group J Clin Oncol 24 4991 4997 (Pubitemid 46631401)
10. YF Chang LL Li CW Wu WY Liu FK P'eng CW Chi 1996 Paclitaxel induced apoptosis in human gastric carcinoma cell lines Cancer 77 14 18 (Pubitemid 26002731)
11. S Maeda Y Saikawa T Kubota M Aoki Y Otani T Furukawa M Watanabe K Kumai M Kitajima 2003 No cross-resistance of taxotere and taxol to conventional chemotherapeutic agents against gastric cancers as detected by MTT assay Anticancer Res 23 3147 3150 (Pubitemid 36975407)
12. J Schüller J Cassidy E Dumont B Roos S Durston L Banken M Utoh K Mori E Weidekamm B Reigner 2000 Preferential activation of capecitabine in tumor following oral administration in colorectal cancer patients Cancer Chemother Pharmacol 45 291 297 (Pubitemid 30151522)
13. J Ajani 2006 Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers Cancer 107 221 231 (Pubitemid 44043103)
14. N Sawada T Ishikawa Y Fukase M Nishida T Yoshikubo H Ishitsuka 1998 Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts Clin Cancer Res 4 1013 1019 (Pubitemid 28183404)
15. MA Villalona-Calero JL Blum SE Jones S Diab R Elledge P Khoury D Von Hoff M Kraynak J Moczygemba P Kromelis T Griffin EK Rowinsky 2001 A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients Ann Oncol 12 605 614 (Pubitemid 32519911)
16. A Webb D Cunningham JH Scarffe P Harper A Norman JK Joffe M Hughes J Mansi M Findlay A Hill J Oates M Nicolson T Hickish M O'Brien T Iveson M Watson C Underhill M Meehan 1997 Randomized trial comparing epirubicin, cisplatin, and 5 fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer J Clin Oncol 15 261 267 (Pubitemid 27020582)
17. U Vanhoefer P Rougier H Wilke MP Ducreux AJ Lacave E Van Cutsem M Planker JG Santos P Piedbois B Paillot H Bodenstein HJ Schmoll H Bleiberg B Nordlinger ML Couvreur B Baron JA Wils 2000 Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group J Clin Oncol 18 2648 2657 (Pubitemid 30465650)
18. TR Fleming 1982 One sample multiple testing procedures for phase II clinical trials Biometrics 43 143 151
19. JM Park YJ Jang JH Kim SS Park SH Park SJ Kim YJ Mok CS Kim 2008 Gastric cancer histology: clinicopathologic characteristics and prognosis value J Surg Oncol 98 520 525
20. S Cascinu F Graziano N Cardarelli M Marcellini P Giordani EP Menichetti G Catalano 1998 Phase II study of paclitaxel in pretreated advanced gastric cancer Anticancer Drugs 9 307 310 (Pubitemid 28241819)
21. K Yamaguchi M Tada N Horikoshi T Otani H Takuichi S Saitoh R Kanamaru Y Kasai W Koizumi Y Sakata T Taguchi 2002 Phase II study of paclitaxel with 3-h infusion in patients with advanced gastric cancer Gastric Cancer 5 90 95 (Pubitemid 34832243)
22. Y Kodera S Ito Y Mochizuchi S Fujitake K Koshikawa Y Kanyama T Matsui H Kojima T Takase N Ohashi M Fujiwara J Sakamoto N Akimasa Chubu Clinical Cancer Group 2007 A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric cancer Cancer 27 2267 2271
23. SY Hong SY Song SI Lee HC Chung SH Choi SH Noh JN Park JY Han JH Kang KS Lee JY Cho 2004 A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer Ann Oncol 15 1344 1347 (Pubitemid 39295021)
24. J Sakamoto K Chin K Kondo H Kojima M Terashima Y Yamamura T Tsujinoka I Hyodo W Koizumi Clinical Study Group of Capecitabine 2006 Phase II study of a 4-week capecitabin regimen in advanced or recurrent gastric cancer Anticancer Drugs 17 231 236
25. W Koizumi K Saigenji S Ujiie M Terashima Y Sakata 2003 Taguchi T Clinical Study Group of Capecitabine: a pilot phase II study of capecitabine in advanced or recurrent gastric cancer Oncology 64 232 236
26. HJ Kang HM Chang TW Kim MH Ryu HJ Sohn JH Yook ST Oh BS Kim JS Lee YK Kang 2008 A phase II study of paclitaxel and capecitabine as first-line combination chemotherapy for advanced gastric cancer Br J Cancer 98 316 322 (Pubitemid 351161266)
27. JP Gustalla III V Diéras 2003 The taxanes: toxicity and quality of life considerations in advanced ovarian cancer Br J Cancer 89 S16 S22
28. G Rosati D Bilancia D Germano A Dinota R Romano G Reggiardo L Manzione 2007 Reduced dose intensity of docetaxel plus capecitabine as second-line palliative chemotherapy in patients with metastatic gastric cancer: a phase II study Ann Oncol 18 128 132
29. C Kollmannsberger D Quietzsch C Haag T Lingenfelser M Schroeder JT Hartmann W Baronius V Hempel M Clemens L Kanz C Bokemeyer 2000 A phase II study of paclitaxel, weekly, 24-h continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer Br J Cancer 83 458 462 (Pubitemid 30487857)
30. CK Im HC Jeung SY Rha NC Yoo SH Noh JK Roh HC Chung 2008 A phase II study of paclitaxel combined with infusional 5-fluorouracil and low-dose leucovorin for advanced gastric cancer Cancer Chemother Pharmacol 61 315 321 (Pubitemid 350160330)
31. HJ Lee Y Cho do JC Park SB Bae KT Lee IS Cho CS Han SY Park HJ Yun S Kim 2009 Phase II trial of biweekly paclitaxel plus infusional 5-fluorouracil and leucovorin in patients with advanced or recurrent inoperable gastric cancer Cancer Chemother Pharmacol 63 427 432
32. JA Ajani 2008 Optimizing docetaxel chemotherapy in patients with cancer of the gastric and gastrooesophageal junction Cancer 113 945 965
33. SH Park WK Lee M Chung Y Lee SH Han SM Bang EK Cho DB Shin JH Lee 2006 Paclitaxel versus docetaxel for advanced gastric cancer: a randomized phase II trial in combination with infusional 5-fluorouracil Anticancer Drugs 17 225 229